# EDGAR Filing Document

**Accession Number:** 0001042074
**File Stem:** 0001193125-23-077974
**Filing Date:** 2023-3
**Character Count:** 19086
**Document Hash:** c88894141d289b1f345e5678d43cd6dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-077974.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0001193125-23-077974

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**EFFECTIVENESS DATE**: 20230323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CymaBay Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042074
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 943103561
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270795
- **FILM NUMBER:** 23756810

**BUSINESS ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560
- **BUSINESS PHONE:** 510-293-8800

**MAIL ADDRESS:**
- **STREET 1:** 7575 GATEWAY BOULEVARD
- **STREET 2:** SUITE 110
- **CITY:** NEWARK
- **STATE:** CA
- **ZIP:** 94560

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX, INC.
- **DATE OF NAME CHANGE:** 20090721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** METABOLEX INC
- **DATE OF NAME CHANGE:** 19970710

**As filed with the Securities and Exchange Commission on March 23, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## CYMABAY THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **94-3103561** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**7575 Gateway Blvd., Suite 110** 

**Newark, California 94560** 

**(Address of principal executive offices) (Zip code)** 

**CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan** 

**(Full title of the plan)** 

**Sujal Shah** 

**President and Chief Executive Officer** 

**CymaBay Therapeutics, Inc.** 

**7575 Gateway Boulevard, Suite 110** 

**Newark, California 94560** 

**(510) 293-8800**

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)** 

------

***Copies to:***

**Matthew B. Hemington** 

**Brett D. White** 

**Cooley LLP** 

**3175 Hanover Street** 

**Palo Alto, California 94304** 

**(650) 843-5000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

CymaBay Therapeutics, Inc. (the "***Registrant***") is filing this Registration Statement on Form S-8 for the purpose of registering an additional 4,234,053 shares of its Common Stock, issuable to eligible persons under the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan ("***2013 Plan***"), which Common Stock is in addition to the shares of Common Stock previously registered on the following Form S-8s (collectively, the "***Prior Form S-8s***"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312514140266/d704606ds8.htm) filed on April 11, 2014 (File No. 333-195211);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312514317253/d778715ds8.htm) filed on August 21, 2014 (File No. 333-198289);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312515101942/d893060ds8.htm) filed on March 23, 2015 (File No. 333-202941);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312516521477/d168162ds8.htm) filed on March 29, 2016 (File No. 333-210453);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312517093773/d312937ds8.htm) filed on March 23, 2017 (File No. 333-216905);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312518084086/d549907ds8.htm) filed on March 15, 2018 (File No. 333-223687);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312518244510/d560209ds8.htm) filed on August 9, 2018 (File No. 333-226741);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312519057404/d713178ds8.htm) filed on February 28, 2019 (File No. 333-229953);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312521094503/d116787ds8.htm) filed on March 25, 2021 (File No. 333-254697); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the Registrant's [Form S-8](http://www.sec.gov/Archives/edgar/data/1042074/000119312522078370/d302181ds8.htm) filed on March 17, 2022 (File No. 333-263644).

------

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Documents by Reference.** <br>

The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

**(a)** The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1042074/000119312523077859/d446975d10k.htm) for the fiscal year ended December 31, 2022 filed with the SEC on March 23, 2023.

**(b)** The description of the Registrant's Common Stock that is contained in a registration statement on [<u>Form 8-A</u>](http://www.sec.gov/Archives/edgar/data/1042074/000119312514237040/d741110d8a12b.htm)filed with the SEC on June 16, 2014, including any amendment or report filed for the purpose of updating such description, including [Exhibit 4.2](http://www.sec.gov/Archives/edgar/data/1042074/000119312521094424/d41924dex42.htm) to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 25, 2021.

**(c)** All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.** <br>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** | **Incorporation by Reference** |
| <br>**Exhibit<br>Number** | <br>**Description** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation](http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex31.htm) | 10 | 000-55021 | 3.1 | 10/17/2013 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation](http://www.sec.gov/Archives/edgar/data/1042074/000119312520180903/d938886dex31.htm) | 8-K | 001-36500 | 3.1 | 6/26/2020 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Amended and Restated Bylaws](http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex32.htm) | 10 | 000-55021 | 3.2 | 10/17/2013 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Cooley LLP.](d468152dex51.htm) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;23.1\* | [Consent of Independent Registered Public Accounting Firm.](d468152dex231.htm) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;23.2\* | [Consent of Cooley LLP (reference is made to Exhibit 5.1).](d468152dex51.htm) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;24.1\* | [Power of Attorney (reference is made to the signature page hereto).](d468152ds8.htm#sig) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;99.1 | [CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1042074/000119312518186789/d594001dex101.htm) | 8-K | 001-36500 | 10.1 | 6/7/2018 |
| 107\* | [Filing Fee Table.](d468152dexfilingfees.htm) |  |  |  |  |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newark, State of California, on March 23, 2023.

---

| | |
|:---|:---|
| **CYMABAY THERAPEUTICS, INC.** | **CYMABAY THERAPEUTICS, INC.** |
| By: | /s/ Sujal Shah |
|  | Sujal Shah |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Sujal A. Shah, Daniel Menold and Paul Quinlan, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name and Signature** | **Title** | **Date** |
| /s/ Sujal Shah<br> Sujal Shah | President, Chief Executive Officer and Director<br> *(Principal Executive Officer)* | March 23, 2023 |
| /s/ Daniel Menold<br> Daniel Menold | Vice President, Finance<br> *(Principal Financial and Accounting Officer)* | March 23, 2023 |
| /s/ Robert J. Wills<br> Robert J. Wills, Ph.D. | Chairman of the Board and Director | March 23, 2023 |
| /s/ Janet Dorling<br> Janet Dorling | Director | March 23, 2023 |
| /s/ Éric Lefebvre<br> Éric Lefebvre | Director | March 23, 2023 |
| /s/ Caroline Loewy<br> Caroline Loewy | Director | March 23, 2023 |
| /s/ Kurt von Emster<br> Kurt von Emster | Director | March 23, 2023 |
| /s/ Thomas G. Wiggans<br> Thomas G. Wiggans | Director | March 23, 2023 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g468152g0322033556102.jpg)

Matthew B. Hemington

+1 650 843 5062

hemingtonmb@cooley.com

March 23, 2023

CymaBay Therapeutics, Inc.

7575 Gateway Boulevard, Suite 110

Newark, CA 94560

Ladies and Gentlemen:

We have acted as counsel to CymaBay Therapeutics, Inc., a Delaware corporation (the "***Company***") in connection with the filing of a Registration Statement on Form S-8 (the "***Registration Statement***") with the

Securities and Exchange Commission covering the offering of up to 4,234,053 shares (the "***Shares***") of the Company's Common Stock, par value $0.0001 per share, issuable pursuant to the Company's 2013 Equity Incentive Plan (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plan, (c) the Company's certificate of incorporation and bylaws, each as currently in effect and (d) originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and related prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

------

![LOGO](g468152g0322033556102.jpg)

CymaBay Therapeutics, Inc.

March 23, 2023

Page Two

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **COOLEY LLP** | **COOLEY LLP** |
| By: | /s/ Matthew B. Hemington |
|  | Matthew B. Hemington |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2013 Equity Incentive Plan of our report dated March 23, 2023, with respect to the consolidated financial statements of CymaBay Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

---

| |
|:---|
| /s/ Ernst & Young LLP |
| San Mateo, California |
| March 23, 2023 |

---

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Table** 

**Form S-8** 

(Form Type)

**CymaBay Therapeutics, Inc.** 

(Exact name of Registrant as specified in its charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Security Type** | **Title of Securities**<br> **to be Registered** | **Fee<br>Calculation<br>Rule** | **Amount**<br> **to be<br>Registered(1)** | **Proposed<br>Maximum<br>Offering**<br> **Price**<br> **Per Share** | **Proposed**<br> **Maximum<br>Aggregate**<br> **Offering**<br> **Price** | **Fee Rate** | **Amount of**<br> **Registration<br>Fee** |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, $0.0001 par value per share | Other (3) | 3042539 (2) | $8.94 (3) | $27200299  | $110.20 per<br> $1,000,000 | $2997.47 |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock, $0.0001 par value per share | Other (4) | 1191514 (2) | $7.63 (4) | $9091252 | $110.20 per<br> $1,000,000 | $1001.86 |
|  | **TOTAL** |  | 4234053 |  | $36291551 |  | $3999.33 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the " <u>Securities Act</u> "),
this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the plans set forth herein as a result of any stock dividend, stock split, recapitalization, or other similar transaction
effected without the receipt of consideration that results in an increase to the number of outstanding shares of Registrant's common stock.

(2) Represents additional shares of common stock available for issuance under the Registrant's 2013 Equity
Incentive Plan pursuant to the evergreen provisions of such plan.

(3) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and
(h) under the Securities Act on the basis of $8.94 per share with respect to shares reserved for future grant, which is the average of the high and low prices of a share of the Registrant's common stock on the Nasdaq Global Select Market
on March 22, 2023

(4) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) under the
Securities Act on the basis of $7.63 per share with respect to outstanding options, which is the combined weighted-average exercise price for outstanding options granted under the Registrant's 2013 Equity Incentive Plan.